152 related articles for article (PubMed ID: 31842358)
21. Antiviral activity of topoisomerase II catalytic inhibitors against Epstein-Barr virus.
Wu T; Wang Y; Yuan Y
Antiviral Res; 2014 Jul; 107():95-101. PubMed ID: 24821256
[TBL] [Abstract][Full Text] [Related]
22. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.
Verma D; Thompson J; Swaminathan S
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3609-14. PubMed ID: 26976570
[TBL] [Abstract][Full Text] [Related]
23. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.
Tikhmyanova N; Schultz DC; Lee T; Salvino JM; Lieberman PM
ACS Chem Biol; 2014 Mar; 9(3):785-95. PubMed ID: 24028149
[TBL] [Abstract][Full Text] [Related]
24. Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets.
De Leo A; Arena G; Lacanna E; Oliviero G; Colavita F; Mattia E
Antiviral Res; 2012 Nov; 96(2):196-202. PubMed ID: 22985630
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel inducer for EBV lytic therapy.
Tikhmyanova N; Paparoidamis N; Romero-Masters J; Feng X; Mohammed FS; Reddy PAN; Kenney SC; Lieberman PM; Salvino JM
Bioorg Med Chem Lett; 2019 Aug; 29(16):2259-2264. PubMed ID: 31255485
[TBL] [Abstract][Full Text] [Related]
26. Flavonoids from the aerial parts of Macrothelypteris torresiana.
Fang W; Ruan J; Cai Y; Wei A; Zhou D; Zhang W
Nat Prod Res; 2011 Jan; 25(1):36-9. PubMed ID: 21240759
[TBL] [Abstract][Full Text] [Related]
27. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
28. [Effect of isonicotinic acid derivates on reproduction of Epstein-Barr virus].
Zahorodnia SD; Nesterova NV; Danylenko VP; Bukhtiarova TA; Baranova HV; Holovan' AV
Mikrobiol Z; 2011; 73(2):65-72. PubMed ID: 21598662
[TBL] [Abstract][Full Text] [Related]
29. Semisynthesis of (-)-Rutamarin Derivatives and Their Inhibitory Activity on Epstein-Barr Virus Lytic Replication.
Lin Y; Wang Q; Gu Q; Zhang H; Jiang C; Hu J; Wang Y; Yan Y; Xu J
J Nat Prod; 2017 Jan; 80(1):53-60. PubMed ID: 28093914
[TBL] [Abstract][Full Text] [Related]
30. The effect of Astragalus polysaccharide on the Epstein-Barr virus lytic cycle.
Guo Q; Sun X; Zhang Z; Zhang L; Yao G; Li F; Yang X; Song L; Jiang G
Acta Virol; 2014; 58(1):76-80. PubMed ID: 24717032
[TBL] [Abstract][Full Text] [Related]
31. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.
Li H; Hu J; Luo X; Bode AM; Dong Z; Cao Y
Cancer Sci; 2018 Jul; 109(7):2101-2108. PubMed ID: 29751367
[TBL] [Abstract][Full Text] [Related]
32. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
33. Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.
Davies AH; Grand RJ; Evans FJ; Rickinson AB
J Virol; 1991 Dec; 65(12):6838-44. PubMed ID: 1658377
[TBL] [Abstract][Full Text] [Related]
34. Bioactive constituents of Lindernia crustacea and its anti-EBV effect via Rta expression inhibition in the viral lytic cycle.
Tsai YC; Hohmann J; El-Shazly M; Chang LK; Dankó B; Kúsz N; Hsieh CT; Hunyadi A; Chang FR
J Ethnopharmacol; 2020 Mar; 250():112493. PubMed ID: 31863859
[TBL] [Abstract][Full Text] [Related]
35. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
[TBL] [Abstract][Full Text] [Related]
37. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
[TBL] [Abstract][Full Text] [Related]
38. Effect of Pinus massoniana Lamb. bark extract on lytic cycle of Epstein-Barr virus.
Xu S; Zhang S; Wang X; Gao Y; Qin X; Wu K
Indian J Exp Biol; 2012 Oct; 50(10):708-13. PubMed ID: 23214264
[TBL] [Abstract][Full Text] [Related]
39. The antagonism between apigenin and protoapigenone to the PDK-1 target in Macrothelypteris torresiana.
Liu Z; Cao S; Jin C; He Y; Zhou X; Zhang H; Liu Z
Fitoterapia; 2019 Apr; 134():14-22. PubMed ID: 30731149
[TBL] [Abstract][Full Text] [Related]
40. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
